{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:46:36Z","timestamp":1777463196677,"version":"3.51.4"},"reference-count":42,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T00:00:00Z","timestamp":1336694400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p>Anticoagulant drugs are taken by millions of patients throughout the world. Warfarin has been the most widely prescribed anticoagulant for decades. In recent years, new oral anticoagulants have been approved for use, are being positioned as alternatives to warfarin, and represent an enormous market opportunity for pharmaceutical companies. Requests for urgent reversal of anticoagulants are not uncommon especially in the setting of critical bleeding. This review summarizes information on reversal of warfarin by vitamin\u2003K, plasma, prothrombin complex concentrates, and recombinant VIIa. In addition, we emphasize the lack of current evidence supporting reversibility of the new oral direct thrombin inhibitors and Factor Xa inhibitors. This review is presented to assist transfusion medicine specialists, hematologists, and other clinicians who prescribe blood components for reversal of drug\u2010induced anticoagulation.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03690.x","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T21:09:43Z","timestamp":1336770583000},"source":"Crossref","is-referenced-by-count":45,"title":["Reversal of drug\u2010induced anticoagulation: old solutions and new problems"],"prefix":"10.1111","volume":"52","author":[{"given":"Walter \u201cSunny\u201d","family":"Dzik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,11]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316075"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04321.x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.185"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2721"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-4-200208200-00009"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.20.2469"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011237019082"},{"key":"e_1_2_9_9_2","volume-title":"Technical manual","author":"Roback JD","year":"2011"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000195047.21562.23"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2295"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01859.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q096"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02080.x"},{"key":"e_1_2_9_15_2","first-page":"148","article-title":"Emergency reversal of anticoagulation with a three\u2010factor prothrombin complex concentrate in patients with intracranial haemorrhage","volume":"9","author":"Imberti D","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_9_16_2","first-page":"117","article-title":"Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?","volume":"9","author":"Makris M","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.3171\/2011.11.JNS11836"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02816.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199911000-00020"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-01-0052"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.23.7.972"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655992"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/02688690050175265"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01339.x"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.05.011"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.593541"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253492"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12245-009-0125-8"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1112874"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.624650"},{"issue":"2","key":"e_1_2_9_34_2","first-page":"P\u2010W\u2010652","article-title":"Recombinant factor VIIA partially reverses the anticoagulant effect of high\u2010dose rivaroxaban\u2014a novel, oral, direct factor XA inhibitor\u2014in rats [abstract]","volume":"5","author":"Tinel HH","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_9_35_2","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated prothrombin complex concentrate [abstract]","volume":"93","author":"van Ryn J","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_9_36_2","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.V118.21.2316.2316","article-title":"The successful reversal of dabigatran\u2010induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation [abstract]","volume":"118","author":"van Ryn J","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_37_2","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood.V112.11.3825.3825","article-title":"Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates [abstract]","volume":"112","author":"Gruber A","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393587"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.3171\/2012.2.JNS112132"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1112874"},{"key":"e_1_2_9_41_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.V114.22.1065.1065","article-title":"Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract]","volume":"114","author":"van Ryn J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318170-000000000-00000"},{"key":"e_1_2_9_43_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.V112.11.983.983","article-title":"Recombinant antidote for reversal of anticoagulation by Factor Xa inhibitors [abstract]","volume":"112","author":"Lu G","year":"2008","journal-title":"Blood"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03690.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03690.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:08:57Z","timestamp":1694563737000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03690.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":42,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03690.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03690.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}